{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:25:54Z","timestamp":1757611554296,"version":"3.44.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>We present the case of a young 38-year-old woman with metastatic progressive pancreatic neuroendocrine neoplasm (NEN) exhibiting an unusual metastasis to the parotid gland. After previous treatments, including radionuclide therapy with the somatostatin-receptor agonist DOTATOC and parotid metastasectomy, failed, she was referred to TANDEM peptide receptor radionuclide therapy (PRRT) using the somatostatin-receptor antagonist DOTA-LM3 labeled with Actinium-225 and Lutetium-177. Following 2 cycles of TANDEM-PRRT, she achieved partial remission in all metastatic sites, notably in the parotid gland and liver. This is the first reported case of metastatic pancreatic NEN with parotid involvement treated with TANDEM-PRRT.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005782","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T01:00:57Z","timestamp":1741309257000},"page":"e605-e607","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["TANDEM Peptide Receptor Radionuclide Therapy Using [225Ac]Ac-\/[177Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8404-8206","authenticated-orcid":false,"given":"Elisabetta","family":"Perrone","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"},{"name":"Department of Radiological Sciences and Hematology, Institute of Nuclear Medicine, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Ghai","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandr","family":"Eismant","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"R1-20250903","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.suronc.2017.11.007","article-title":"Metastases to the parotid gland\u2014a review of the clinicopathological evolution, molecular mechanisms and management","volume":"27","author":"Badlani","year":"2018","journal-title":"Surg Oncol"},{"key":"R2-20250903","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3390\/cancers15041293","article-title":"Primary and secondary tumors of the parotid gland: clinical features and prognosis","volume":"15","author":"Pecorari","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R3-20250903","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/10668969221095267","article-title":"Metastatic neuroendocrine tumors to parotid gland: where do they come from?","volume":"31","author":"Braun","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"R4-20250903","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12105-013-0431-6","article-title":"Moderately differentiated neuroendocrine carcinoma (atypical carcinoid) of the parotid gland: report of three cases with contemporary review of salivary neuroendocrine carcinomas","volume":"7","author":"Said-Al-Naief","year":"2013","journal-title":"Head Neck Pathol"},{"key":"R5-20250903","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ol.2014.2258","article-title":"Primary neuroendocrine small cell carcinoma of the parotid gland: a case report and review of the literature","volume":"8","author":"Liu","year":"2014","journal-title":"Oncol Lett"},{"key":"R6-20250903","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s12105-021-01300-0","article-title":"Primary large cell neuroendocrine carcinoma of the parotid gland. Report of a rare case","volume":"15","author":"Tosios","year":"2021","journal-title":"Head Neck Pathol"},{"key":"R7-20250903","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2967\/jnmt.120.251587","article-title":"Poorly differentiated neuroendocrine carcinoma of the parotid gland and moderately differentiated hepatic metastases: a discordant histopathology clarified by dual-tracer PET\/CT","volume":"49","author":"Sharma","year":"2021","journal-title":"J Nucl Med Technol"},{"key":"R8-20250903","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250903","first-page":"1232","article-title":"Ac-225-DOTATOC\u2014an empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors","volume":"56","author":"Kratochwil","year":"2015","journal-title":"J Nucl Med"},{"key":"R10-20250903","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med"},{"key":"R11-20250903","doi-asserted-by":"crossref","first-page":"1034315","DOI":"10.3389\/fmed.2022.1034315","article-title":"Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists","volume":"9","author":"Shi","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:00:36Z","timestamp":1756933236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005782","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"2024-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}